Primary and secondary outcomes

Table S3 – Primary and secondary outcomes evaluated in this review

Primary outcomes
The number of participants with any adverse event and participants with ART-related adverse events (as defined in the studies): - Discontinuation or dropouts/withdrawals of treatment; - Clinical and/or laboratory adverse events; - Clinical adverse events; - Laboratory adverse events.
Secondary outcomes
The number of participants with any adverse event and participants with ART-related adverse events (as defined in the studies): - Grade 3 and/or 4 clinical and/or laboratory adverse events; - Grade 3 and/or 4 clinical adverse events; - Grade 3 and/or 4 laboratory adverse events; - Grade 3 clinical and/or laboratory adverse events; - Grade 3 clinical adverse events; - Grade 3 laboratory adverse events; - Grade 4 clinical and/or laboratory adverse events; - Grade 4 clinical adverse events; - Grade 4 laboratory adverse events; - Serious clinical and/or laboratory adverse events; - Serious clinical adverse events; - Serious laboratory adverse events; - Delay in puberty; - Amenorrhea; - Menstrual irregularity; - Early menopause; - Total with hot flashes; - Total with severe hot flushes; - Total with moderate hot flashes; - Total with light hot flashes; - Total with severe/moderate hot flashes; - Total with moderate/light hot flashes; - Osteopenia; - Osteoporosis; - General fractures due to osteoporosis; - Vertebral fractures due to osteoporosis; - Non-vertebral fractures due to osteoporosis; - Wrist fractures due to osteoporosis; - Hip fractures due to osteoporosis; - Hospitalization for adverse events. Death from all causes; ART-related death.